Showing results (311-320 of 534) with videos related to
Sort By:
Pageof 54
Leukemia & Lymphoma|August 9, 2025
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phaseOmer Karrar, Hagop Kantarjian, Fadi G Haddad, et al.Clinical Lymphoma, Myeloma & Leukemia|July 2, 2026
Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic LeukemiaWei-Ying Jen, Elias Jabbour, Eitan Kugler, et al.Cancer|July 22, 2026
Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemiaHagop Kantarjian, Wei-Ying Jen, Eitan Kugler, et al.British Journal of Pharmacology|December 22, 1999
Pharmacological characterization of antagonists of the C5a receptorN J Paczkowski, A M Finch, J B Whitmore, et al.American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.Chronic Illness|April 20, 2023
Perceptions of mindfulness practices as a support for individuals managing caregiving responsibilities and chronic disease: A qualitative studyNathan T West, Brook E Harmon, Kristen E Rawlett, et al.Journal of Hematology & Oncology|May 14, 2025
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomabNicholas J Short, Hagop Kantarjian, Ken Furudate, et al.Scientific Reports|July 23, 2024
Intergenerational effects of racism on amygdala and hippocampus resting state functional connectivityT R A Kral, C Y Williams, A C Wylie, et al.Cancer|February 21, 2025
Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaEitan Kugler, Hagop Kantarjian, Elias Jabbour, et al.Pharmacoepidemiology and Drug Safety|February 9, 2010
Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured populationPeter M Wahl, Keith Rodgers, Sebastian Schneeweiss, et al.Pageof 54